Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Severe COVID-19 (CORON-ACT)
NCT04335071Phase 2Terminated
- Sponsor
- Insel Gruppe
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Actemra with Placebo (2 arms). Primary endpoints: Number of patients with ICU admission at 7 days, Number of patients with intubation at 14 days and 1 more. Started Apr 2020; status: terminated.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04335071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335071.